New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLiraglutide vs Dermorphin

Liraglutide vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Recovery & Repair
Dermorphin
Summary
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
~13 hours (once-daily dosing)
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
SubQ
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
Start 0.6 mg, titrate to 3 mg
Not established for human use; research doses vary widely
Frequency
Once daily
Not established
Key Benefits
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With